Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier and get trading ideas, historical data, advanced options screeners, more. FREE 30 Day Trial

Stocks | Futures | Watchlist | More
or

Iveric Bio Inc (ISEE)

Iveric Bio Inc (ISEE)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 2,156,105
  • Shares Outstanding, K 118,078
  • Annual Sales, $ 0 K
  • Annual Income, $ -114,520 K
  • 60-Month Beta 0.97
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 6.97
Trade ISEE with:

Options Overview Details

View History
  • Implied Volatility 95.61% ( -10.30%)
  • Historical Volatility 167.70%
  • IV Percentile 70%
  • IV Rank 11.44%
  • IV High 420.09% on 09/01/22
  • IV Low 53.71% on 04/11/22
  • Put/Call Vol Ratio 0.18
  • Today's Volume 3,195
  • Volume Avg (30-Day) 23,005
  • Put/Call OI Ratio 0.44
  • Today's Open Interest 170,922
  • Open Int (30-Day) 210,735

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 11 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/22
See More
  • Average Estimate -0.40
  • Number of Estimates 7
  • High Estimate -0.28
  • Low Estimate -0.50
  • Prior Year -0.23
  • Growth Rate Est. (year over year) -73.91%

Price Performance

See More
Period Period Low Period High Performance
1-Month
12.28 +48.70%
on 09/06/22
20.99 -13.01%
on 09/09/22
+8.82 (+93.43%)
since 09/02/22
3-Month
8.95 +104.02%
on 07/05/22
20.99 -13.01%
on 09/09/22
+8.86 (+94.26%)
since 07/01/22
52-Week
8.85 +106.33%
on 06/13/22
20.99 -13.01%
on 09/09/22
+1.61 (+9.67%)
since 10/01/21

Most Recent Stories

More News
Iveric Bio to Present Top-line Results for Avacincaptad Pegol from Phase 3 GATHER2 Clinical Trial in Geographic Atrophy at AAO 2022 Annual Meeting

IVERIC bio, Inc. (Nasdaq: ISEE) announced today that top-line efficacy and safety results from GATHER2, the Company’s second Phase 3 clinical trial of avacincaptad pegol (ACP, also known as Zimura ®...

ISEE : 18.26 (+1.78%)
Why Iveric Bio Stock Is Skyrocketing This Week

Investors are applauding the company's late-stage clinical results for its lead pipeline candidate.

ISEE : 18.26 (+1.78%)
IVERIC bio (ISEE) Posts Positive Top-Line Data From GA Study

IVERIC bio (ISEE) reports positive top-line data from the phase III GATHER2 study, evaluating its investigational candidate, Zimura, for the treatment of geographic atrophy. Stock up.

ATRA : 3.85 (+1.85%)
ISEE : 18.26 (+1.78%)
ORIC : 3.15 (-1.56%)
ACHL : 2.27 (+0.44%)
Why Is Karuna Therapeutics, Inc. (KRTX) Up 8.4% Since Last Earnings Report?

Karuna Therapeutics, Inc. (KRTX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

KRTX : 229.60 (+2.08%)
ISEE : 18.26 (+1.78%)
Iveric Bio to Present at Upcoming Investor Conferences

IVERIC bio, Inc. (Nasdaq: ISEE) announced today that Glenn P. Sblendorio, Chief Executive Officer, and Pravin U. Dugel, M.D., President, will participate in fireside chats at the following two investor...

ISEE : 18.26 (+1.78%)
Iveric Bio (NASDAQ: ISEE) Reports Positive Topline Phase 3 Trial Data for Zimura, Plans to Submit FDA New Drug Application Q1 2023

Iveric Bio, Inc. (NASDAQ: ISEE) is engaged as a biopharmaceutical company, which is focused on the research and development of

ISEE : 18.26 (+1.78%)
The 2 Stocks Everyone's Talking About Tuesday

The market looked poised to bounce after the long weekend.

COMP : 2.44 (+5.17%)
$NASX : 10,815.43 (+2.27%)
ADT : 7.78 (+3.87%)
ISEE : 18.26 (+1.78%)
Iveric Bio Announces Positive Topline Data from Zimura® GATHER2 Phase 3 Clinical Trial in Geographic Atrophy

IVERIC bio, Inc. (Nasdaq: ISEE) today announced positive topline results from GATHER2, the Company’s second Phase 3 clinical trial of Zimura ® (avacincaptad pegol), a novel investigational complement...

ISEE : 18.26 (+1.78%)
Iveric Bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

IVERIC bio, Inc. (NASDAQ: ISEE) today reported that on September 1, 2022, the Company granted equity-based awards pursuant to the Company’s 2019 Inducement Stock Incentive Plan to two newly-hired, non-executive...

ISEE : 18.26 (+1.78%)
Iveric Bio to Participate in the H.C. Wainwright 2nd Annual Ophthalmology Virtual Conference

IVERIC bio, Inc. (Nasdaq: ISEE) announced today that Pravin U. Dugel, M.D., President, will participate in a panel discussion titled, “Differentiation in Emerging Treatments for GA dAMD -- Perspectives...

ISEE : 18.26 (+1.78%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 88% Buy with a Strongest short term outlook on maintaining the current direction.

See More Share

Business Summary

IVERIC bio Inc. is a biotechnology company. It is focused on the discovery and development of novel gene therapy solutions to treat orphan inherited retinal diseases. IVERIC bio Inc., formerly known as Ophthotech Corporation, is based in New York, United States.

See More

Key Turning Points

3rd Resistance Point 20.62
2nd Resistance Point 19.93
1st Resistance Point 19.09
Last Price 18.26
1st Support Level 17.56
2nd Support Level 16.87
3rd Support Level 16.03

See More

52-Week High 20.99
Last Price 18.26
Fibonacci 61.8% 16.35
Fibonacci 50% 14.92
Fibonacci 38.2% 13.49
52-Week Low 8.85

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar